Abstract:
The present invention relates to a method for preparing an protein monolayer using a peptide hybrid for protein immobilization, more precisely a peptide hybrid for protein immobilization which has improved solubility by introducing a PEG linker and a proper reaction group to the oligopeptide having specific affinity to selected types of proteins and is designed to provide enough space between solid substrates and proteins immobilized, whereby various solid substrates treated by the hybrid catch specific proteins effectively on. The peptide hybrid for protein immobilization of the present invention facilitates the control of orientation of an antibody on various solid surfaces and immobilization of various antibodies of different origins or having different isotypes with different affinity. Therefore, the surface treatment technique using the peptide hybrid of the invention can be effectively used for the production of various immunosensors and immune chips.
Abstract:
Isolated peptide substrates of Plk1 and nucleic acids encoding these peptides are disclosed. The peptides include two to ten repeats of the amino acid sequence set forth as X1X2AX3X4X5PLHSTX6X7X8X9X10X11X12 (SEQ ID NO: 1), in which within each repeat X1, X2, X6, X7, X8, X9, X10, X11, and X12 are each independently any amino acid or no amino acid, and X3 and X4 are each independently any amino acid. Methods of using these peptides to detect Plk1 activity in a sample are also disclosed. In some examples, the method includes contacting a sample with a disclosed peptide substrate of Plk1 in the presence of adenosine triphosphate, or an analog thereof, for a period of time sufficient for Plk1 to phosphorylate the PBIPtide. The presence and/or amount of the phosphorylated and/or the unphosphorylated peptide is detected, thereby detecting and/or quantitating Plk1 kinase activity in the sample.
Abstract translation:公开了Plk1的分离的肽底物和编码这些肽的核酸。 肽包括X1X2AX3X4X5PLHSTX6X7X8X9X10X11X12(SEQ ID NO:1)所示的氨基酸序列的2至10个重复,其中每个重复X1,X2,X6,X7,X8,X9,X10,X11和X12各自独立地 任何氨基酸或不含氨基酸,X3和X4各自独立地为任何氨基酸。 还公开了使用这些肽检测样品中Plk1活性的方法。 在一些实例中,该方法包括在三磷酸腺苷或其类似物的存在下将样品与公开的Plk1肽底物接触足以使Plk1磷酸化PBIPtide的时间。 检测磷酸化和/或未磷酸化肽的存在和/或量,从而检测和/或定量样品中的Plk1激酶活性。
Abstract:
The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.
Abstract:
The present invention relates to an N-terminal cysteine-tagged Streptococcal protein G variant. Since the variant binds in a directional manner to a surface of a biochip or a biosensor, the variant provides a biochip and a biosensor having an improved antibody-immobilizing capability, compared with an untagged protein G variant.
Abstract:
The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
Abstract:
An in vitro high-throughput screening method that models the absorption of drugs across the epithelial mucosa is provided. The invention discloses an in vitro mucin immobilized chromatography model to estimate drug permeability coefficients. The invention describes compositions for mucin immobilized chromatography media and methods to prepare this media. The invention also discloses a method to estimate in vitro drug permeability coefficients using mucin immobilized chromatography media. The invention also discloses methods to determine absorption processes in the digestive system and discloses methods of use for mucin chromatography media in column, batch, assay, diagnostic, or high-throughput screening analyses.
Abstract:
Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism.
Abstract:
Novel peptide having a sequence according to SEQ. ID. No. 1, SEQ. ID. No. 2 and/or SEQ. ID. No. 3 are disclosed and also polypeptide scaffold consisting of a four helix bundle formed of two dimerized helix-loop-helix motifs, said helix-loop-helix motifs having sequences according to SEQ. ID. No. 1, SEQ. ID. No. 2 and/or SEQ. ID. No. 3 which may comprise a fluorescent probe at the side chain of Lys15 and a ligand with affinity for a target molecule at the side chain of Lys8 or Lys34.Also disclosed are polypeptide scaffolds for use in biosensing applications with or without the polypeptide scaffold anchored to a solid surface.
Abstract:
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Abstract:
Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.